Donepezil for the Treatment of Agitation in Alzheimer's Disease | Zendy

Robert Howard | Zendy; Edmund Juszczak | Zendy; Clive Ballard | Zendy; Peter Bentham | Zendy; Richard G. Brown | Zendy; Roger Bullock | Zendy; Alistair Burns | Zendy; Clive Holmes | Zendy; Robin Jacoby | Zendy; Tony Johnson | Zendy; Martín Knapp | Zendy; James Lindesay | Zendy; John T. O’Brien | Zendy; Gordon Wilcock | Zendy; Cornelius Katona | Zendy; Roy Jones | Zendy; Julia DeCesare | Zendy; Michaela Rodger | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Donepezil for the Treatment of Agitation in Alzheimer's Disease

Author(s) -

Robert Howard,

Edmund Juszczak,

Clive Ballard,

Peter Bentham,

Richard G. Brown,

Roger Bullock,

Alistair Burns,

Clive Holmes,

Robin Jacoby,

Tony Johnson,

Martín Knapp,

James Lindesay,

John T. O’Brien,

Gordon Wilcock,

Cornelius Katona,

Roy Jones,

Julia DeCesare,

Michaela Rodger

Publication year - 2007

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa066583

Subject(s) - donepezil , placebo , medicine , clinical global impression , psychomotor agitation , alzheimer's disease , anesthesia , psychiatry , dementia , disease , alternative medicine , pathology

Agitation is a common and distressing symptom in patients with Alzheimer's disease. Cholinesterase inhibitors improve cognitive outcomes in such patients, but the benefits of these drugs for behavioral disturbances are unclear.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research